Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313778 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by ModernaTX.
- Active
- Registry status
- Phase 1
- Development phase
- 161
- Enrollment target
- 20
- Study locations
NCT03313778 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 161 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT03313778, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 161 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL mRNA-4157
- BIOLOGICAL SoC Treatment
Study Locations (20)
Florida
- Orlando Health Cancer Institute - Orlando
- Florida Cancer Specialists - Sarasota
- H Lee Moffitt Cancer Center and Research Institute - Tampa
New South Wales
- St Vincents Hospital Sydney - Darlinghurst
- Westmead Hospital-Cnr Hawkesbury and Darcy Road - Westmead
Other
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research - Tokyo
- Imperial College Healthcare NHS Trust Hammersmith Hospital - London
California
- Angeles Clinic and Research Institute - Los Angeles
District of Columbia
- The George Washington Cancer Center - Washington D.C.
Massachusetts
- Massachusetts General Hospital - Boston
New York
- NYU Langone Medical Center - New York
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2027-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03313778
The ClinicalTrials.gov registry entry for NCT03313778 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (43% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03313778 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, New South Wales, Other.
Frequently Asked Questions
What is clinical trial NCT03313778 about?
NCT03313778 is a clinical study titled "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors". The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
What is the current status of trial NCT03313778?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 161 participants. The study started on 2017-08-14. Estimated completion is 2027-11-21.
What conditions does trial NCT03313778 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT03313778?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), mRNA-4157 (BIOLOGICAL), SoC Treatment (BIOLOGICAL).
Who is sponsoring clinical trial NCT03313778?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03313778 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.